152 related articles for article (PubMed ID: 16334167)
1. Biochemical nature and mapping of PSMA epitopes recognized by human antibodies induced after immunization with gene-based vaccines.
Todorova K; Zoubak S; Mincheff M; Kyurkchiev S
Anticancer Res; 2005; 25(6C):4727-32. PubMed ID: 16334167
[TBL] [Abstract][Full Text] [Related]
2. Humoral immune response in prostate cancer patients after immunization with gene-based vaccines that encode for a protein that is proteasomally degraded.
Todorova K; Ignatova I; Tchakarov S; Altankova I; Zoubak S; Kyurkchiev S; Mincheff M
Cancer Immun; 2005 Jan; 5():1. PubMed ID: 15641767
[TBL] [Abstract][Full Text] [Related]
3. DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen.
Vittes GE; Harden EL; Ottensmeier CH; Rice J; Stevenson FK
Eur J Immunol; 2011 Aug; 41(8):2447-56. PubMed ID: 21604260
[TBL] [Abstract][Full Text] [Related]
4. Immune responses against PSMA after gene-based vaccination for immunotherapy-A: results from immunizations in animals.
Mincheff M; Zoubak S; Makogonenko Y
Cancer Gene Ther; 2006 Apr; 13(4):436-44. PubMed ID: 16276349
[TBL] [Abstract][Full Text] [Related]
5. Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo.
Medin JA; Liang SB; Hou JW; Kelley LS; Peace DJ; Fowler DH
Cancer Gene Ther; 2005 Jun; 12(6):540-51. PubMed ID: 15678150
[TBL] [Abstract][Full Text] [Related]
6. A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses.
Durso RJ; Andjelic S; Gardner JP; Margitich DJ; Donovan GP; Arrigale RR; Wang X; Maughan MF; Talarico TL; Olmsted RA; Heston WD; Maddon PJ; Olson WC
Clin Cancer Res; 2007 Jul; 13(13):3999-4008. PubMed ID: 17606734
[TBL] [Abstract][Full Text] [Related]
7. A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer.
Slovin SF; Kehoe M; Durso R; Fernandez C; Olson W; Gao JP; Israel R; Scher HI; Morris S
Vaccine; 2013 Jan; 31(6):943-9. PubMed ID: 23246260
[TBL] [Abstract][Full Text] [Related]
8. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.
Elsässer-Beile U; Wolf P; Gierschner D; Bühler P; Schultze-Seemann W; Wetterauer U
Prostate; 2006 Sep; 66(13):1359-70. PubMed ID: 16894535
[TBL] [Abstract][Full Text] [Related]
9. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial.
Mincheff M; Tchakarov S; Zoubak S; Loukinov D; Botev C; Altankova I; Georgiev G; Petrov S; Meryman HT
Eur Urol; 2000 Aug; 38(2):208-17. PubMed ID: 10895014
[TBL] [Abstract][Full Text] [Related]
10. Human dendritic cells genetically engineered to express cytosolically retained fragment of prostate-specific membrane antigen prime cytotoxic T-cell responses to multiple epitopes.
Mincheff M; Zoubak S; Altankova I; Tchakarov S; Makogonenko Y; Botev C; Ignatova I; Dimitrov R; Madarzhieva K; Hammett M; Pomakov Y; Meryman H; Lissitchkov T
Cancer Gene Ther; 2003 Dec; 10(12):907-17. PubMed ID: 14712317
[TBL] [Abstract][Full Text] [Related]
11. Isolation and characterization of monoclonal antibodies specific for protein conformational epitopes present in prostate-specific membrane antigen (PSMA).
Tino WT; Huber MJ; Lake TP; Greene TG; Murphy GP; Holmes EH
Hybridoma; 2000 Jun; 19(3):249-57. PubMed ID: 10952413
[TBL] [Abstract][Full Text] [Related]
12. Effective targeting of prostate cancer by lymphocytes redirected by a PSMA × CD3 bispecific single-chain diabody.
Fortmüller K; Alt K; Gierschner D; Wolf P; Baum V; Freudenberg N; Wetterauer U; Elsässer-Beile U; Bühler P
Prostate; 2011 May; 71(6):588-96. PubMed ID: 20945402
[TBL] [Abstract][Full Text] [Related]
13. DNA vaccines: an active immunization strategy for prostate cancer.
Wolchok JD; Gregor PD; Nordquist LT; Slovin SF; Scher HI
Semin Oncol; 2003 Oct; 30(5):659-66. PubMed ID: 14571413
[TBL] [Abstract][Full Text] [Related]
14. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
[TBL] [Abstract][Full Text] [Related]
15. Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination.
Gregor PD; Wolchok JD; Turaga V; Latouche JB; Sadelain M; Bacich D; Heston WD; Houghton AN; Scher HI
Int J Cancer; 2005 Sep; 116(3):415-21. PubMed ID: 15800947
[TBL] [Abstract][Full Text] [Related]
16. PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth.
Su Y; Yu L; Liu N; Guo Z; Wang G; Zheng J; Wei M; Wang H; Yang AG; Qin W; Wen W
Cancer Lett; 2013 Sep; 338(2):282-91. PubMed ID: 23752065
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen.
Huang X; Bennett M; Thorpe PE
Prostate; 2004 Sep; 61(1):1-11. PubMed ID: 15287089
[TBL] [Abstract][Full Text] [Related]
18. Preparation and characterization of new anti-PSMA monoclonal antibodies with potential clinical use.
Moffett S; Mélançon D; DeCrescenzo G; St-Pierre C; Deschénes F; Saragovi HU; Gold P; Cuello AC
Hybridoma (Larchmt); 2007 Dec; 26(6):363-72. PubMed ID: 18158780
[TBL] [Abstract][Full Text] [Related]
19. Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy.
Ma Q; Safar M; Holmes E; Wang Y; Boynton AL; Junghans RP
Prostate; 2004 Sep; 61(1):12-25. PubMed ID: 15287090
[TBL] [Abstract][Full Text] [Related]
20. Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer.
Murphy GP; Kenny GM; Ragde H; Wolfert RL; Boynton AL; Holmes EH; Misrock SL; Bartsch G; Klocker H; Pointner J; Reissigl A; McLeod DG; Douglas T; Morgan T; Gilbaugh J
Urology; 1998 May; 51(5A Suppl):89-97. PubMed ID: 9610563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
